Allianz Asset Management GmbH Has $9.26 Million Stake in Alkermes PLC (ALKS)

Allianz Asset Management GmbH trimmed its stake in Alkermes PLC (NASDAQ:ALKS) by 5.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 182,152 shares of the company’s stock after selling 11,306 shares during the period. Allianz Asset Management GmbH owned 0.12% of Alkermes worth $9,261,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ALKS. Dimensional Fund Advisors LP increased its stake in Alkermes by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 194,531 shares of the company’s stock worth $11,381,000 after buying an additional 2,891 shares in the last quarter. US Bancorp DE increased its stake in Alkermes by 366.4% in the 2nd quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after buying an additional 3,122 shares in the last quarter. Janney Montgomery Scott LLC purchased a new stake in Alkermes in the 2nd quarter worth $554,000. IFP Advisors Inc increased its stake in Alkermes by 10.9% in the 2nd quarter. IFP Advisors Inc now owns 4,074 shares of the company’s stock worth $236,000 after buying an additional 402 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in Alkermes by 20.2% in the 2nd quarter. Canada Pension Plan Investment Board now owns 135,558 shares of the company’s stock worth $7,858,000 after buying an additional 22,758 shares in the last quarter. Hedge funds and other institutional investors own 99.69% of the company’s stock.

Alkermes PLC (NASDAQ ALKS) opened at $52.62 on Friday. Alkermes PLC has a 1-year low of $46.42 and a 1-year high of $63.40. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.04. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The business had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same quarter in the prior year, the firm earned ($0.09) EPS. The business’s revenue was up 20.6% on a year-over-year basis. equities analysts forecast that Alkermes PLC will post -0.59 earnings per share for the current fiscal year.

In other Alkermes news, SVP Michael J. Landine sold 15,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $48.71, for a total transaction of $730,650.00. Following the completion of the transaction, the senior vice president now owns 178,693 shares of the company’s stock, valued at approximately $8,704,136.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $50.64, for a total transaction of $75,960.00. The disclosure for this sale can be found here. Insiders have sold a total of 109,364 shares of company stock valued at $5,355,310 in the last three months. Insiders own 5.34% of the company’s stock.

ALKS has been the subject of a number of analyst reports. Jefferies Group set a $69.00 price target on Alkermes and gave the stock a “buy” rating in a research note on Friday, August 25th. Credit Suisse Group set a $66.00 price target on Alkermes and gave the stock a “buy” rating in a research note on Tuesday, November 28th. J P Morgan Chase & Co set a $78.00 price target on Alkermes and gave the stock a “buy” rating in a research note on Friday, October 27th. Mizuho set a $81.00 price target on Alkermes and gave the stock a “buy” rating in a research note on Saturday, October 21st. Finally, Barclays lowered Alkermes from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $66.00 to $50.00 in a research note on Monday, October 16th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. Alkermes presently has a consensus rating of “Hold” and an average target price of $63.55.

WARNING: This news story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/12/17/allianz-asset-management-gmbh-has-9-26-million-stake-in-alkermes-plc-alks.html.

Alkermes Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply